Roche’s Genentech Inc. is expanding its research initiatives in neuroscience through a collaboration with pain start-up Xenon Pharmaceuticals Inc. In a deal announced Jan. 9, Genentech said it would work with Xenon to discover and develop compounds and companion diagnostics for the treatment of pain, a therapeutic area that is relatively new to Genentech.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?